Shuttle system ascent aerodynamic and plume heating

The shuttle program provided a challenge to the aerothermodynamicist due to the complexity of the flow field around the vehicle during ascent, since the configuration causes multiple shock interactions between the elements. Wind tunnel tests provided data for the prediction of the ascent design heating environment which involves both plume and aerodynamic heating phenomena. The approach for the heating methodology based on ground test firings and the use of the wind tunnel data to formulate the math models is discussed

Data report for tests on the heat transfer effects of the 0.0175-scale Rockwell International space shuttle vehicle model 22-OT in the AEDC 50-inch B wind tunnel (OH4B), volume 2

For abstract, see N75-18290

The Adsorption and Collapse Transitions in a Linear Polymer Chain near an Attractive Wall

We deduce the qualitative phase diagram of a long flexible neutral polymer chain immersed in a poor solvent near an attracting surface using phenomenological arguments. The actual positions of the phase boundaries are estimated numerically from series expansion up to 19 sites of a self-attracting self avoiding walk in three dimensions. In two dimensions, we calculate analytically phase boundaries in some cases for a partially directed model. Both the numerical as well as analytical results corroborate the proposed qualitative phase diagram.Comment: 8 pages, 8 figures, revte

Data report for tests on the heat transfer effects of the 0.0175 scale Rockwell International Space Shuttle Vehicle model 22-OT in the AEDC 50 inch B wind tunnel (0H4B), volume 1

Results of wind tunnel heat transfer tests of 0.0175-scale Rockwell International Space Shuttle Vehicle configurations for orbiter alone, tank alone, and orbiter plus external tank are presented. Body flap shielding of SSME's during simulated entry was investigated. The tests were conducted at Mach 8 for thirteen Reynolds number

Data report for tests on the heat transfer effects of the 0.0175-scale Rockwell International Space Shuttle Vehicle model 22-OT in the AEDC 50-inch B wind tunnel (OH4B), volume 3

Results of wind tunnel heat transfer tests of 0.0175-scale Rockwell International Space Shuttle Vehicle configurations for orbiter alone, tank alone, and orbiter plus external tank are presented. Body flap shielding of SSME's during simulated entry was also investigated. The tests were conducted at Mach 8 for thirteen Reynolds number per foot values ranging from 0.5 million to 3.72 million

Thermal protection system gap heating rates of the Rockwell International flat plate heat transfer model (OH2A/OH2B)

Heat transfer data for the Rockwell International Flat Plate Thermocouple Model are presented. The model simulated the Space Shuttle Vehicle Thermal Protection System. Data were recorded for locations in and around various size gaps for various gap orientation configurations. The test was conducted at Mach 5.1 for free-stream Reynolds number per foot values from 500,000 to 1,500,000

Heat transfer test of an 0.006-scale thin-skin thermocouple space shuttle model (50-0, 41-T) in the NASA-Ames Research Center 3.5-foot hypersonic wind tunnel at Mach 5.3 (IH28), volume 1

Data obtained from a heat transfer test conducted on an 0.006-scale space shuttle orbiter and external tank in the NASA-Ames Research Center 3.5-foot Hypersonic Wind Tunnel are presented. The purpose of this test was to obtain data under simulated return-to-launch-site abort conditions. Configurations tested were integrated orbiter and external tank, orbiter alone, and external tank alone at angles of attack of 0, + or - 30, + or - 60, + or - 90, and + or - 120 degrees. Runs were conducted at Mach numbers of 5.2 and 5.3 for Reynolds numbers of 1.0 and 4.0 million per foot, respectively. Heat transfer data were obtained from 75 orbiter and 75 external tank iron-constantan thermocouples

Heat transfer of an 0.006-scale thin-skin thermocouple space shuttle model (50-0, 41-T) in the NASA-Ames Research Center 3.5-foot hypersonic wind tunnel at Mach 5.3 (IH28), volume 2

For abstract, see N76-32230

Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.

BackgroundCabozantinib, an orally bioavailable inhibitor of tyrosine kinases including MET, AXL, and VEGF receptors, was assessed in patients with hepatocellular carcinoma (HCC) as part of a phase 2 randomized discontinuation trial with nine tumor-type cohorts.Patients and methodsEligible patients had Child-Pugh A liver function and ≤1 prior systemic anticancer regimen, completed ≥4 weeks before study entry. The cabozantinib starting dose was 100 mg daily. After an initial 12-week cabozantinib treatment period, patients with stable disease (SD) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 were randomized to cabozantinib or placebo. The primary endpoint of the lead-in stage was objective response rate (ORR) at week 12, and the primary endpoint of the randomized stage was progression-free survival (PFS).ResultsAmong the 41 HCC patients enrolled, the week 12 ORR was 5%, with 2 patients achieving a confirmed partial response (PR). The week 12 disease control rate (PR or SD) was 66% (Asian subgroup: 73%). Of patients with ≥1 post-baseline scan, 78% had tumor regression, with no apparent relationship to prior sorafenib therapy. Alpha-fetoprotein (AFP) response (>50% reduction from baseline) occurred in 9 of the 26 (35%) patients with elevated baseline AFP and ≥1 post-baseline measurement. Twenty-two patients with SD at week 12 were randomized. Median PFS after randomization was 2.5 months with cabozantinib and 1.4 months with placebo, although this difference was not statistically significant. Median PFS and overall survival from Day 1 in all patients were 5.2 and 11.5 months, respectively. The most common grade 3/4 adverse events, regardless of attribution, were diarrhea (20%), hand-foot syndrome (15%), and thrombocytopenia (15%). Dose reductions were utilized in 59% of patients.ConclusionsCabozantinib has clinical activity in HCC patients, including objective tumor responses, disease stabilization, and reductions in AFP. Adverse events were managed with dose reductions.Trial registration numberNCT00940225